Subject(s)
Mesencephalon/pathology , Supranuclear Palsy, Progressive/pathology , Aged, 80 and over , Atrophy/pathology , Atrophy/physiopathology , Diagnosis, Differential , Humans , Hypokinesia/etiology , Magnetic Resonance Imaging , Male , Mesencephalon/physiopathology , Muscle Rigidity/etiology , Ocular Motility Disorders/etiology , Supranuclear Palsy, Progressive/physiopathologySubject(s)
Kluver-Bucy Syndrome/microbiology , Kluver-Bucy Syndrome/pathology , Temporal Lobe/microbiology , Temporal Lobe/pathology , Whipple Disease/complications , Whipple Disease/pathology , Amygdala/microbiology , Amygdala/pathology , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/therapeutic use , Ceftriaxone/therapeutic use , Dementia/microbiology , Dementia/pathology , Diagnosis, Differential , Female , Humans , Kluver-Bucy Syndrome/physiopathology , Magnetic Resonance Imaging , Middle Aged , Paresis/microbiology , Paresis/pathology , Treatment Outcome , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Whipple Disease/drug therapyABSTRACT
The selection of human monoclonal antibodies (MAbs) specific for human immunodeficiency virus (HIV) type 1 by binding assays may fail to identify Abs to quaternary epitopes on the intact virions. The HIV neutralization assay was used for the selection of human MAb 2909, which potently neutralizes SF162 and recognizes an epitope on the virus surface but not on soluble proteins. Three regions of gp120, the V2 and V3 loops and the CD4 binding domain, contribute to the epitope recognized by MAb 2909. The existence of such a unique MAb, which defines a complex epitope formed by a quaternary structure, suggests that there may be other new neutralizing HIV epitopes to target with vaccines.
Subject(s)
Epitopes/chemistry , HIV Envelope Protein gp120/immunology , HIV-1/immunology , Antibodies, Monoclonal , Cell Line , Cell Line, Tumor , Enzyme-Linked Immunosorbent Assay , HIV Envelope Protein gp120/chemistry , Humans , Neutralization Tests , Protein Structure, Quaternary , Virion/immunology , Virion/physiologyABSTRACT
The chemokine receptor CCR5 is constitutively associated with the T cell co-receptor CD4 in plasma cell membranes. The CD4-CCR5 complex exhibits distinct binding properties for macrophage inflammatory protein 1beta (MIP-1beta) and enhanced G-protein signaling as compared with those of CCR5 alone. Here we report that recombinant soluble CD4, when refolded into its dimeric form, allosterically modulates CCR5 and decreases the affinity for its natural ligand MIP-1beta. Monomeric soluble CD4 had little inhibitory effect on CCR5. In contrast, the two-domain amino-terminal fragment of soluble CD4 was able to completely inhibit the interaction of CCR5 with MIP-1beta. Thus, we suggest that various conformational states of CD4 exist, which differ markedly with regard to inhibiting the interaction of CCR5 with its ligand MIP-1beta. R5-tropic HIV-1 glycoprotein 120, but not interleukin-16, the natural agonist, or X4-tropic glycoprotein 120, inhibited MIP-1beta binding to CCR5 in the presence of monomeric and dimeric soluble CD4.
Subject(s)
CD4 Antigens/metabolism , Receptors, CCR5/metabolism , Binding, Competitive , CD4 Antigens/chemistry , CD4 Antigens/genetics , Chemokine CCL4 , Dimerization , Humans , Kinetics , Ligands , Macrophage Inflammatory Proteins/metabolism , Recombinant Proteins/metabolism , Tumor Cells, CulturedABSTRACT
The chemokine receptor CCR5 is constitutively associated with the T cell co-receptor CD4 in plasma cell membranes, but the physiological role of this interaction has not been elucidated. Here we show that detergent-solubilized, purified CCR5 can directly associate with purified soluble fragments of the extracellular portion of CD4. We further demonstrate that the physical association of CCR5 and CD4 in membrane vesicles results in the formation of a receptor complex that exhibits macrophage inflammatory protein 1beta (MIP-1beta) binding properties that are distinct from CCR5. The affinity of the CD4-CCR5 complex for MIP-1beta was 3.5-fold lower than for CCR5, but the interaction of CD4 and CCR5 resulted in a receptor complex that exhibited enhanced G-protein signaling as compared with CCR5 alone. MIP-1beta-induced G-protein activation was further increased by simultaneous stimulation of CD4 with its natural agonist, interleukin-16. Thus, the physical association of CD4 and CCR5 results in receptor cross-talk with allosteric CD4-dependent regulation of the binding and signaling properties of CCR5. Although the precise physiological role of the CD4 effects on CCR5-mediated signaling remains unknown, one can speculate that the cross-talk is a component of mechanisms involved in the fine tuning of immune system cell responses.
